Purpose

This study will evaluate the efficacy of transcranial magnetic stimulation in the treatment of Tourette's Syndrome for patients who have not fully responded to conventional therapies.

Type of Study: Clinical Trial
Setting of Study: outpatient
Clinical Trials.gov number: NCT00529308
Providing Clinical Treatment?: Yes
No Cost Treatment?: Yes
Care is provided in languages: English

Study Activities

Filling Out Forms
Computer Tasks
Blood Samples

Eligibility

Ages Eligible for Study: 18 Years - 70 Years
Genders Eligible for Study: Both
This study is not recruiting Healthy Volunteers.

Criteria

Inclusion Criteria:
* Primary diagnosis of Tourette's Syndrome, as confirmed by the DSM-IV-TR criteria
* Residual TS symptoms, defined as a total Y-GTSS total motor tic or phonic tic score > 20, despite treatment with an adequate trial of medications (defined as a failure to respond to a trial of commonly used medications for TS such as clonidine, guanfacine, or neuroleptic medications, given at recommended dosage and duration based on the clinician's judgment)
* Persistent high level of tic severity for 4 months despite efforts to control the tics using medications OR the presence of self injurious tics
* Duration of the index episode of at least a year
* Individuals who cannot tolerate medications of class and dose at the specified duration as described above will also be included.
* Patients currently on medication must be at the same stable dose(s) for one month prior to enrollment and be willing to continue at the same dose(s) through the duration of the study.

Links
The Tourette Syndrome Association provides information to and advocates on behalf of patients with TS.
Division of Brain Stimulation and Therapeutic Modulation home page
Study summary on Division of Brain Stimulation and Therapeutic Modulation web site

Location: 1051 Riverside Drive, Box #21 New York, NY 10032
Clinic: Novel Treatments for Depression Service
Division: Other

Study chairs or principal investigators:
Antonio Mantovani MD, Principal Investigator

Co-investigators:
Sarah Lisanby,
James Leckman,
Ralph Hoffman,
Rodolfo Llinas,
Bradley Peterson